Health
Question mark over effectiveness of Pfizer-BioNTech COVID-19 vaccine in obese people – BioPharma-Reporter.com
New data may have serious implications for the development of vaccination strategies for COVID-19, particularly in individuals with obesity.
A study by a team of researchers based at Istituti Fisioterapici Ospitalieri (IFO) in Rome, Italy, aimed to analyse the antibody response following two doses of the Pfizer/BioNTech COVID-19 vaccine, BNT162B2, in 248 healthcare workers. They also looked to evaluate how the antibody titer in those participants changed in relation to age, gender and body mass index (BMI).
Of the cohort studied, 158 were women (63.7%) and 90 were men (36.3%). The average age was 47 years, with the range going from 23…
-
Noosa News19 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General22 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General21 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Noosa News11 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership